Bone marrow

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

Retrieved on: 
Monday, March 25, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Toxicity, CDK7, Apoptosis, Hebrew University of Jerusalem, CRH, CRi, AML, Patient, Immunology, Acute myeloid leukemia, Cancer, Medicine, Alta Partners, Therapy, Drug development, Breast cancer, Safety, Azacitidine, Pharmacokinetics, CDK9, Bone marrow, Pharmaceutical industry

Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.

Key Points: 
  • Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.
  • “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients.
  • In a Phase 1 study in heavily pre-treated R/R AML patients, monotherapy BTX-A51 demonstrated a favorable safety profile and encouraging antileukemic activity.
  • As a next step, Edgewood initiated a study of BTX-A51 in combination with azacitidine in R/R AML patients in December 2023.

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Retrieved on: 
Tuesday, March 26, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Philanthropy, Clinical Trials, Well, Diagnosis, BMY, World Health Organization, Patients Association, Less, Organization, Social, Education, Bone marrow, Survival, Health equity, Social support, Genetics, Patient, Good Health, Corporate Affairs, Pancreatic cancer, Cancer, Anti-transglutaminase antibodies, Bristol Myers Squibb, Blood Cancer UK, United, Telephone numbers in Hungary, Sistema, Oral cancer, Clinical trial, WHO, Multimedia, Hepatocellular carcinoma, Nursing

Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.
  • The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 .
  • At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being.
  • Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Retrieved on: 
Wednesday, March 20, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ID, Webcast, Syros, Bone marrow

ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Key Points: 
  • ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
  • To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 21905455.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .
  • An archived replay of the webcast will be available for approximately 30 days following the call.

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Retrieved on: 
Friday, March 15, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, SOC, MCL, Index, DHL, Patient, Neoplasm, Artificial intelligence, AI, Sarcoma, Human, NHL, Mantle cell lymphoma, Clinical trial, Bone marrow, Safety, Pharmacokinetics, MTD, Machine learning, FDA, DLBCL, Pharmaceutical industry

“Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.

Key Points: 
  • “Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.
  • Patients will be enrolled and treated with LP-284 administered intravenously (IV) on Days 1, 8, 15 of a 28-day schedule.
  • Up to 30 patients will be enrolled in Phase 1a; the total number of patients will depend on the number of dose levels explored.
  • Additionally, Lantern may enroll up to 40 patients in each of the two cohorts of MCL and HGBL (including DLBCL) tumors in Phase 1b.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Retrieved on: 
Thursday, March 14, 2024
Research, Hospitals, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Bone marrow, Patient, Transfusion-dependent anemia, Corporation, Imetelstat, ODAC, Anemia, Geron Corporation, MDS, Food, Medicine, Pharmaceutical industry

“We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.

Key Points: 
  • “We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.
  • Additionally, a sustained increase in mean hemoglobin levels in imetelstat-treated patients was observed over time compared to placebo patients.
  • The ODAC provides the FDA with independent opinions and recommendations from outside medical experts, patients and caregivers, though the recommendations are not binding.
  • Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval.

Deepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform Launch

Retrieved on: 
Wednesday, March 13, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Artificial Intelligence, Science, Biotechnology, Stem Cells, Health, Gene, Flow cytometry, Gene expression, Intelligence, Cell biology, Allergy, Newcastle University, Developmental biology, Doctor of Philosophy, Genotype, EMBL, Axon, Eosinophil, Cognition, Neutrophil, Liver cancer, Machine learning, European, Bone marrow, Microscope

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .

Key Points: 
  • Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .
  • The participants will use the technology to study plasma disorders, blood cancers, immunological functions, genetic perturbations, and other cellular processes.
  • The REM-I platform is a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, an AI Foundation Model, and Axon data suite.
  • “Deepcell's method of integrating artificial intelligence and single cell analysis remains unique in the industry,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Friday, March 15, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SLL, BMY, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Bone marrow, Caregiver, Patient, Lymphocytosis, City, CRS, Commercial, Bristol Myers Squibb, BTK, MRD, Cytokine release syndrome, Division, Drug resistance, Multimedia, Blood, Associate professor, Food, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
  • After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Philanthropy, Health, Foundation, Pharmaceutical, Cardiology, Biotechnology, Diagnosis, Bone marrow, Chronic lymphocytic leukemia, Entrepreneurship, CLL, Health equity, Patient, Humanitarianism, Cancer, Leukemia, BeiGene, Access, Multimedia, Physician, Developing country, Medicine, Pharmaceutical industry

As a member of the Humanitarian PACT, BeiGene provided a monetary grant through the BeiGene Foundation and is providing BRUKINSA free of charge for eligible patients in a number of low- and middle-income countries.

Key Points: 
  • As a member of the Humanitarian PACT, BeiGene provided a monetary grant through the BeiGene Foundation and is providing BRUKINSA free of charge for eligible patients in a number of low- and middle-income countries.
  • “BeiGene and Max share a commitment to advance global health equity and ensure that patients in underserved regions have access to the best possible cancer care.
  • BeiGene and Max aim to provide access to CLL treatment to patients in need in 29 low- and middle-income countries.
  • Upon patient identity verification and CLL diagnosis confirmation, Max will deliver the treatment directly to the health institution providing care to the patient through well-established supply chains.

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

Retrieved on: 
Wednesday, March 13, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, Head, Survival, Massachusetts General Hospital, AML, Patient, Doctor of Philosophy, MD, PRTC, HMA, Hospital, Bone marrow, MDS, Immunoglobulin G, Food, Person, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYT-200 for the treatment of AML.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYT-200 for the treatment of AML.
  • LYT-200 is a fully human IgG4 monoclonal antibody (mAb) targeting galectin-9, a potent oncogenic driver in leukemia cells and an immunosuppressive protein.
  • “Orphan drug designation from the FDA validates our belief that targeting galectin-9 with LYT-200 is a novel, promising approach that may offer patients a better tolerated, more effective treatment,” notes Aleksandra Filipovic, MD, PhD, Head of Oncology at PureTech.
  • The FDA grants orphan drug designation to novel drug and biologic products for the treatment, diagnosis, or prevention of conditions affecting fewer than 200,000 persons in the U.S. Orphan drug designation qualifies PureTech for incentives under the Orphan Drug Act, including tax credits for some clinical trials and eligibility for seven years of market exclusivity in the U.S., if the drug is approved for AML.